Rep. Burgess Discourages Government Intervention On Paying For Cures
Executive Summary
”You may not like what we figure out,” so “I encourage you to do it first,” he tells health care stakeholders.
You may also be interested in...
Trump, Congress And The Search For Common Ground On Drug Pricing
Trump’s ideas for curbing drug pricing have support in Congress but not among those in power; Republican leaders, including the president-elect’s choice for HHS secretary, Tom Price, have long opposed government negotiation in Medicare.
Congress Dives Into Biomedical Innovation: Will It Drown In A Deep Sea Of Competing Needs?
House Energy and Commerce committee says it’s committed to a bill to accelerate U.S. biomedical innovation before the next FDA user fee cycle, but the wide scope of needs and stakeholders may make crafting legislation challenging – never mind getting it passed.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.